Research Paper Volume 13, Issue 17 pp 21102—21121
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Figure 8. Expression levels of BTK, IκBα, P65 and their phosphorylation proteins in the Jeko-1, Rec-1, and Z138 cells after treating with low-dose BGB-3111, low-dose BTZ, and their combination for 48 h.